BrianAndrewJonasMDPhD

Oncology • Sacramento, CA

Hematologic Oncology

Assistant Professor of Medicine, UC Davis Comprehensive Cancer Center

Join to view full profile

Dr. Jonas is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Jonas' full profile

Already have an account?

Office
4501 X St
Ste 3016
Sacramento, CA 95817
Phone+1 916-734-5981

Fax+1 916-734-0631

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 2009 - 2013
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 2007 - 2009
University of California, Davis, School of MedicineClass of 2007

Certifications & Licensure

CA State Medical License 2008 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014

Clinical Trials

Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome Start of enrollment: 2016 May 17
Completed
Phase 1
Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia Start of enrollment: 2017 Jun 27
Recruiting
Phase 2
Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome Start of enrollment: 2017 Dec 01
Completed
Phase 1
Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2019 May 20
Withdrawn
Phase 2
Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2020 May 05
Suspended
Phase 1
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure Start of enrollment: 2022 Feb 09
Recruiting
Phase 2
Roles: Principal Investigator, Sponsor-Investigator, Contact
Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia Start of enrollment: 2021 Jul 02
Recruiting
Phase 1
Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML Start of enrollment: 2018 Aug 15
Recruiting
Phase 3
Roles: Contact
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML Start of enrollment: 2021 May 20
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2019 Mar 11
Recruiting
Phase 1, Phase 2
Roles: Contact
Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction Start of enrollment: 2021 Jan 29
Recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial.
Caspian Oliai, Sunmin Park, Lloyd E Damon, Brian A Jonas, Deepa Jeyakumar
Leukemia & Lymphoma. 2024-12-17
Impact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome-positive acute lymphoblastic leuke...
Talha Badar, Ravi Narra, Alice S Mims, Michael G Heckman, Rory M Shallis
American Journal of Hematology. 2024-12-01
A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort.
Mendel Goldfinger, Ioannis Mantzaris, Aditi Shastri, Yogen Saunthararajah, Kira Gritsman
Blood. 2024-11-28

Journal Articles

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
Courtney D Dinardo, Brian A Jonas, Jacqueline S Garcia, Anthony Letai, Wan-Jen Hong, Keith W Pratz, The New England Journal of Medicine
Venetoclax Combined with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia
Brian A Jonas, Courtney D DiNardo, Olga Frankfurt, Daniel A Pollyea, Keith Pratz, Anthony Letai, Martha Arellano, Marina Konopleva, Hagop M Kantarjian, Blood
Association Between Autologous Stem Cell Transplant and Survival Among Californians with Multiple Myeloma
Aaron S Rosenberg, Brian A Jonas, Journal of the National Cancer Institute

Abstracts/Posters

Incidence of Serious Adverse Events, Pneumonitis, Infection and Sepsis in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphom...
Brian A Jonas, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Phase I Study of Escalating Doses of Carfilzomib with Hyper-CVAD in Patients with Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
Brian A Jonas, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Management of Neutropenia during Venetoclax-Based Combination Treatment in Patients with Newly Diagnosed Acute Myeloid Leukemia
Brian A Jonas, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with R...
Brian A Jonas, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Blinatumomab/Lenalidomide in Relapsed/Refractory Non-HodgkinÍs Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis
Brian A Jonas, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
High E-Selectin Ligand Expression Contributes to Chemotherapy-Resistance in Poor Risk Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML) Patients and Can be Ov...
Brian A Jonas, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients wi...
Brian A Jonas, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Biomarker Modulation By Mivebresib (ABBV-075) +/_ Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia
Brian A Jonas, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Retrospective Analysis of Adults with Acute Myeloid Leukemia Treated with Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Authored Content

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
Join now to see all

Press Mentions

GlycoMimetics Has Few Risks, Great Outlook in LeukemiaApril 4th, 2023
AML Research Continues to Explore Precision Medicine OptionsMarch 3rd, 2023
GlycoMimetics Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia Presented at ASH Annual MeetingDecember 12th, 2022
Join now to see all